Cargando…
Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50%
BACKGROUND: Immune checkpoint inhibitors (ICIs) are standard therapies for patients with advanced non-small-cell lung cancer (NSCLC) and a programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%. Tumor mutation burden (TMB) also predicts response to ICIs but is often not available in rea...
Autores principales: | Gainor, J. F., Rizvi, H., Aguilar, E. Jimenez, Skoulidis, F., Yeap, B. Y., Naidoo, J., Khosrowjerdi, S., Mooradian, M., Lydon, C., Illei, P., Zhang, J., Peterson, R., Ricciuti, B., Nishino, M., Roth, J. A., Grishman, J., Anderson, D., Little, B. P., Carter, B. W., Arbour, K., Sauter, J. L., Mino-Kenudson, M., Heymach, J. V., Digumarthy, S., Shaw, A. T., Awad, M. M., Hellmann, M. D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545963/ https://www.ncbi.nlm.nih.gov/pubmed/32067682 http://dx.doi.org/10.1016/j.annonc.2019.11.015 |
Ejemplares similares
-
Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
por: Mino-Kenudson, Mari
Publicado: (2016) -
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
por: Schoenfeld, A.J., et al.
Publicado: (2019) -
Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer
por: Lopez de Rodas, Miguel, et al.
Publicado: (2022) -
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study
por: Elkrief, Arielle, et al.
Publicado: (2023) -
Immune‐Related Adverse Events in the Setting of PD‐1/L1 Inhibitor Combination Therapy
por: Zubiri, Leyre, et al.
Publicado: (2019)